Safety and efficacy of radiofrequency ablation in desmoid-type fibromatosis

Cover Page

Cite item

Full Text

Abstract

Introduction. Desmoid-type fibromatosis is a rare locally aggressive tumor originating in connective tissue and characterized by locally destructive invasive growth, high recurrence potential and absence of metastases. In recent years, attempts to standardize the treatment of this disease were made but all current therapy methods have disadvantages and do not guarantee absence of disease progression.

 Aim. To evaluate safety and efficacy of radiofrequency ablation in patients with desmoid tumors.

 Materials and methods. The study included 9 adult patients of both genders (4 men and 5 women) aged 21–65 years with morphologically verified diagnosis of desmoid tumor of the soft tissues with extra-abdominal location. All patients in the study group underwent control examination prior to the procedure. The treatment was performed in several stages at low volume (2–50 cm3) taking into account tumor size. Efficacy was determined using pain syndrome regression per the VAS and Watkins scale, as well as Karnofsky Performance Status Scale. Safety was evaluated per the Clavien–Dindo Scale.

 Results. Analysis of pain syndrome dynamics per the VAS and Watkins scale before and after treatment was performed. For both VAS (p = 0.004) and Watkins scale (p = 0.014), statistically significant changes were observed. Pain syndrome decreased to 50 %, and the percentage of patients declining analgesics increased to 66.7 %. Analysis of the performance status per the Karnofsky scale also showed statistically significant changes (p = 0.015). Mean value increased to 90 %. No complications were reported at the time of the study.

 Conclusion. Radiofrequency ablation showed itself to be a safe and effective method for treatment of desmoid tumors. However, further studies are necessary involving more patients.

About the authors

A. M. Galustov

N.  N.  Blokhin  National  Medical  Research  Center  of  Oncology,  Ministry  of  Health  of  Russia

Author for correspondence.
Email: artem115583@mail.ru
ORCID iD: 0000-0002-9019-8369

Artem Maratovich Galustov

24  Kashirskoe  Shosse,  Moscow  115522

Russian Federation

E. A. Sushentsov

N.  N.  Blokhin  National  Medical  Research  Center  of  Oncology,  Ministry  of  Health  of  Russia

ORCID iD: 0000-0003-3672-1742

24  Kashirskoe  Shosse,  Moscow  115522

Russian Federation

D.  I. Sofronov

N.  N.  Blokhin  National  Medical  Research  Center  of  Oncology,  Ministry  of  Health  of  Russia

ORCID iD: 0000-0001-9557-3685

24  Kashirskoe  Shosse,  Moscow  115522

Russian Federation

A. K.  Valiev

N.  N.  Blokhin  National  Medical  Research  Center  of  Oncology,  Ministry  of  Health  of  Russia

ORCID iD: 0000-0002-2038-3729

24  Kashirskoe  Shosse,  Moscow  115522

Russian Federation

V. B. Matveev

N.  N.  Blokhin  National  Medical  Research  Center  of  Oncology,  Ministry  of  Health  of  Russia

ORCID iD: 0000-0001-7748-9527

24  Kashirskoe  Shosse,  Moscow  115522

Russian Federation

A. V. Fedorova

N.  N.  Blokhin  National  Medical  Research  Center  of  Oncology,  Ministry  of  Health  of  Russia

ORCID iD: 0000-0002-4516-3255

24  Kashirskoe  Shosse,  Moscow  115522

Russian Federation

T.  A.  Makarova

N.  N.  Blokhin  National  Medical  Research  Center  of  Oncology,  Ministry  of  Health  of  Russia

ORCID iD: 0000-0002-6274-5636

24  Kashirskoe  Shosse,  Moscow  115522

Russian Federation

B.  Yu.  Bokhyan

N.  N.  Blokhin  National  Medical  Research  Center  of  Oncology,  Ministry  of  Health  of  Russia

ORCID iD: 0000-0002-1396-3434

24  Kashirskoe  Shosse,  Moscow  115522

Russian Federation

A. S. Astafurova

N.  N.  Blokhin  National  Medical  Research  Center  of  Oncology,  Ministry  of  Health  of  Russia

ORCID iD: 0009-0000-6819-4196

24  Kashirskoe  Shosse,  Moscow  115522

Russian Federation

K.  N.  Magomedova

N.  N.  Blokhin  National  Medical  Research  Center  of  Oncology,  Ministry  of  Health  of  Russia

ORCID iD: 0009-0003-6356-9130

24  Kashirskoe  Shosse,  Moscow  115522

Russian Federation

N.  S.  Babkin

N.  N.  Blokhin  National  Medical  Research  Center  of  Oncology,  Ministry  of  Health  of  Russia

ORCID iD: 0000-0003-1395-5132

24  Kashirskoe  Shosse,  Moscow  115522

Russian Federation

References

  1. Clinical guidelines. Soft tissue sarcomas. The Eastern Cooperative Oncology Group, Association of Oncologists of Russia, Russian Society of Clinical Oncology. 2022. (In Russ.).
  2. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Guideline Name V.2.2022. National Comprehensive Cancer Network, Inc. 2022.
  3. Salas S., Dufresne A., Bui B. et al. Prognostic factors influencing progression-free survival determined from a series of sporadic desmoid tumors: a wait-and-see policy according to tumor presentation. J Clin Oncol 2011;29:3553–8. doi: 10.1200/JCO.2010.33.5489
  4. Desmoid Tumor Working Group. The management of desmoid tumours: a joint global consensus-based guideline approach for adult and paediatric patients. Eur J Cancer 2020;127:96–107. doi: 10.1016/j.ejca.2019.11.013
  5. Colombo C., Miceli R., Le Péchoux C. et al. Sporadic extra abdominal wall desmoid-type fibromatosis: surgical resection can be safely limited to a minority of patients. Eur J Cancer 2015;51(2):186–92. doi: 10.1016/j.ejca.2014.11.019
  6. Nоvikova О.V., Daryalova S.L, Boiko L.V., Bychkova N.M. Desmoid fibromas: state-of-the-art. Rossiyskiy onkologicheskiy zhurnal = Russian Journal of Oncology 2008;3:54–5. (In Russ.).
  7. Bychkova N.M., Daryalova S.L., Boiko A.V., Novikova O.V. Desmoid fibromas: the specific features of their clinical course and the results of treatment in male patients. Rossiyskiy onkologicheskiy zhurnal = Russian Journal of Oncology 2009;2:23–30. (In Russ.).
  8. Daryalova S.L., Frank G.A., Karpenko V.Yu. et al. Aggressive fibromatosis – surgical approach as a part of combined treatment. Sarkomy kostei, miagkikh tkanei i opukholi kozhi = Bone and Soft Tissue Sarcomas, Tumors of the Skin 2010;(4):34–9. (In Russ.).
  9. Adamyan A.A., Tokareva T.V., Romashov Yu.V. et al. Surgical treatment of desmoid fibroma and sarcoma of the thoracic and abdominal wall. Khirurgiya. Zhurnal im. N.I. Pirogova = Pirogov Russian Journal of Surgery 2013;(5):12–8. (In Russ.).
  10. Acker J.C., Bossen E.H., Halperin E.C. The management of desmoid tumors. Int J Radiat Oncol Biol Phys 1993;26(5):851–8. doi: 10.1016/0360-3016(93)90501-l
  11. Baumert B.G., Spahr M.O., Von Hochstetter A. et al. The impact of radiotherapy in the treatment of desmoid tumours. An international survey of 110 patients. A study of the Rare Cancer Network. Radiat Oncol 2007;2:12. doi: 10.1186/1748-717X-2-12
  12. Gluck I., Griffith K.A., Biermann J.S. et al. Role of radiotherapy in the management of desmoid tumors. Int J Radiat Oncol Biol Phys 2011;80:787–92. doi: 10.1016/j.ijrobp.2010.02.053
  13. Jelinek J.A., Stelzer K.J., Conrad E. et al. The efficacy of radiotherapy as postoperative treatment for desmoid tumors. Int J Radiat Oncol Biol Phys 2001;50:121–5. doi: 10.1016/s0360-3016(00)01570-4
  14. Duggal A., Dickinson I.C., Sommerville S., Gallie P. The management of extra-abdominal desmoid tumours. Int Orthop 2004;28:252–6. doi: 10.1007/s00264-004-0571-0
  15. Ballo M.T., Zagars G.K., Pollack A. et al. Desmoid tumor: prognostic factors and outcome after surgery, radiation therapy, or combined surgery and radiation therapy. J Clin Oncol 1999;17:158–67. doi: 10.1200/JCO.1999.17.1.158
  16. Guadagnolo B.A., Zagars G.K., Ballo M.T. Long-term outcomes for desmoid tumors treated with radiation therapy. Int J Radiat Oncol Biol Phys 2008;71:441–7. doi: 10.1016/j.ijrobp.2007.10.013
  17. Rüdiger H.A., Ngan S.Y., Ng M. et al. Radiation therapy in the treatment of desmoid tumours reduces surgical indications. Eur J Surg Oncol 2010;36:84–8. doi: 10.1016/j.ejso.2009.07.183
  18. Janinis J., Patriki M., Vini L. et al. The pharmacological treatment of aggressive fibromatosis: a systematic review. Ann Oncol 2003;14:181–90. doi: 10.1093/annonc/mdg064
  19. Al-Jazrawe M., Au M., Alman B. Optimal therapy for desmoid tumors: current options and challenges for the future. Expert Rev Anticancer Ther 2015;15:1443–58. doi: 10.1586/14737140.2015.1096203
  20. Constantinidou A., Jones R.L., Scurr M. et al. Advanced aggressive fibromatosis: effective palliation with chemotherapy. Acta Oncol 2011;50:455–61. doi: 10.3109/0284186X.2010.509105
  21. De Camargo V.P., Keohan M.L., D’Adamo D.R. et al. Clinical outcomes of systemic therapy for patients with deep fibromatosis (desmoid tumor). Cancer 2010;116(9):2258–65. doi: 10.1002/cncr.25089
  22. Keam S.J. Nirogacestat: first approval. Drugs 2024;84(3):355–61. doi: 10.1007/s40265-024-02002-x
  23. Tsz-Kan T., Man-Kwong C., Shu Shang-Jen J. et al. Radiofrequency ablation of recurent fibromatosis. J Vasc Interv Radiol 2007;18(1 Pt 1): 147–50. doi: 10.1016/j.jvir.2006.08.001
  24. Ilaslan H., Schils J., Joyce M. et al. Radiofrequency ablation: another treatment option for local control of desmoid tumors. Skeletal Radiol 2010;39(2):169–73. doi: 10.1007/s00256-009-0807-6
  25. Cobianchi L., Ravetta V., Viera F.T. et al. The challenge of extraabdominal desmoid tumour management in patients with Gardner’s syndrome: radiofrequency ablation, a promising option. World J Surg Oncol 2014;12:361. doi: 10.1186/1477-7819-12-361
  26. Du Y.Q., Bai X.M., Yang W. et al. Percutaneous ultrasound-guided radiofrequency ablation for patients with liver metastasis from pancreatic adenocarcinoma. Int J Hyperthermia 2022;39(1):517–24. doi: 10.1080/02656736.2022.2048907

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2025 Galustov A.M., Sushentsov E.A., Sofronov D.I., Valiev A.K., Matveev V.B., Fedorova A.V., Makarova T.A., Bokhyan B.Y., Astafurova A.S., Magomedova K.N.,  Babkin N.S.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС77-66671 от  09.11.2009.